

Health System Sustainability in Oncology: A European Perspective

November 13th 2023 | Copenhagen



Insights + Innovation + Influence =

**ECONOMIST
IMPACT**

Economist Impact combines the power of evidence-based **insights** and analysis, creative **innovation**, and unmatched global **influence** to turn ideas into action and deliver both business value and world-changing impact.

“Across Europe, 25% of women and 31% of men are expected to be diagnosed with cancer before reaching the age of 75 years”

European Cancer Information System, 2023.

The landscape

- The **increasing age** of the population will underpin a substantial rise in cancer incidence.
- European cancer burden in the 65+ age group is expected to increase by about **38% in terms of new cancer cases** and **44% of cancer deaths from 2020 to 2040**.
- By 2050, it is estimated that a European citizen will **die from cancer every 10 seconds**, but with disparities within the continent, certain parts of Europe may experience a cancer death **every 5 seconds**.




How do we define affordability?

- Defining affordability is challenging, as it is **subjective** and **multidimensional** depending on the perspective of different stakeholders.



How do we measure affordability?


Share of households with catastrophic health spending by consumption quintile, latest year



Note: The EU average is unweighted.
Source: OECD Health at a Glance 2023

How do we measure affordability?


Oncology rate of availability (% , 2018 –2021)



Source: EFPIA Patients W.A.I.T. Indicator 2023 Survey, IQVIA

How do we measure affordability?

Oncology time to availability (2018 –2021)




Source: EFPIA Patients W.A.I.T. Indicator 2023 Survey, IQVIA

How do we seek sustainability?

No universally agreed-upon definition of “health system sustainability”

Author	Definitions or Characteristics
WHO, 2023	“...a broad term to describe policies, projects and investments that provide benefits today without sacrificing environmental, social and personal health in the future.”
Gorman & Horn, 2022	“...the ability to be maintained at a certain rate or level.”
Lehoux et al., 2022	“...1) a healthy population, 2) superior care (“effective, safe, timely, patient-centred, equitable, and efficient”), and (3) fairness, which implies that services are provided “without discrimination or disparities.”
Müller et al., 2021 ¹	“...health care funding mechanism(s), infrastructure and human resources development as well as funding levels of health research.”
Urquhart et al., 2020	“Continued capacity to deliver the innovation, continued delivery of the innovation and continued benefits for the patient, provider, or health system.”
Mortimer et al., 2018	“...refers to the capacity of a health service to deliver healthcare over time, with consideration to future generations.”
Ferrelli et al., 2017 ¹	“...the capacity to endure and can also be defined as a process characterised by the pursuit of a common ideal.”



What steps need to be taken?

Change in policy landscape

- April 2023: European Commission proposed a **pharmaceutical package** to revise the current legislation and make medicines more available, accessible and affordable.
- **New EU HTA Regulation** (EU) 2021/2282 is set to begin in 2025 for advanced therapeutics and oncology assets and be fully implemented by 2030

Multisector collaboration

- **Mission-oriented** approach to cancer: no single country can successfully fight the disease(s) on its own
- **Collaborative European data integration**: national and subregional partnerships to facilitate accurate and timely data collection and sharing



Thank you

Defining affordability and sustainability to revolutionise cancer care



Gerard Dunleavy
Manager, health
policy,
Economist Impact



Shreya Jani
Senior vice-
president, global
corporate affairs,
BeiGene



Simone Boselli
Public affairs
director, EURORDIS



Guillaume Dedet
Senior health
economist,
Organisation for
Economic Co-
operation and
Development (OECD)
Health Division



Rifat Atun
Professor of global
health systems and
director of Health
Systems Innovation
Lab, Harvard
University